Cormorant Asset Management’s Definium Therapeutics DFTX Stock Holding History

Cormorant Asset Management’s Portfolio DFTX Stock Details DFTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$18.8M	Buy	+400,000	New	+$9.88M	0.96%	27

Other funds holding DFTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Cormorant Asset Management's DFTX Position: Q2 2026 in Review

Cormorant Asset Management opened a new position in Definium Therapeutics (DFTX) in Q2 2026: 400,000 shares worth $18.8M. The stake represents 0.96% of the portfolio and ranks #27 among its holdings.

361 funds tracked by Wall St. Rank hold DFTX as of Q2 2026.

Cormorant Asset Management held 400,000 shares of Definium Therapeutics worth $18.8M as of Q2 2026.
Definium Therapeutics was a new Cormorant Asset Management position in Q2 2026.
Definium Therapeutics made up 0.96% of Cormorant Asset Management's portfolio in Q2 2026, its #27 holding.
361 funds tracked by Wall St. Rank held Definium Therapeutics as of Q2 2026.

Based on Cormorant Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.